The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/70385

Please be advised that this information was generated on 2017-09-22 and may be subject to change.
Bone Resorption Inhibitor Alendronate Normalizes the Reduced Bone Thickness of TRPV5−/− Mice

Tom Nijenhuis,1 Bram CJ van der Eerden,2 Joost GJ Hoenderop,1 Harrie Weinans,3 Johannes PTM van Leeuwen,2 and René JM Bindels1

ABSTRACT: TRPV5 is a Ca2+-selective channel involved in transcellular Ca2+ absorption expressed in kidney and in the ruffled border of osteoclasts. Studies in hypercalciuric TRPV5 knockout (TRPV5−/−) mice, which display significantly increased vitamin D levels, showed that TRPV5 ablation increases number and size of osteoclasts but impairs osteoclast-mediated bone resorption. The latter is not in line with the observed decreased bone thickness in TRPV5−/− mice. Bisphosphonates also inhibit osteoclast-mediated bone resorption. The aim of this study was to evaluate the effect of alendronate on the expression of the Ca2+ transporters in bone, kidney, and duodenum and, importantly, the bone phenotype in TRPV5−/− mice. Wildtype (TRPV5+/+) and TRPV5−/− mice were treated during 10 wk with 2 mg/kg alendronate or vehicle weekly and housed in metabolic cages at the end of treatment. Urine and blood samples were taken for biochemical analysis, and duodenum, kidney, and femur were sampled. Expression of Ca2+ transporters and osteoclast ruffled border transporters in bone and cultured osteoclasts was determined by QPCR analysis. Femurs were scanned using μCT, and resorption pit assays were performed in bone marrow cultures isolated from TRPV5+/+ and TRPV5−/− mice. Alendronate treatment enhanced bone thickness in TRPV5+/+ mice but also normalized the disturbed bone morphometry parameters in TRPV5−/− mice. Bone TRPV5 expression was specifically enhanced by alendronate, whereas the expression of Ca2+ transporters in kidney and intestine was not altered. The expression of the osteoclast ruffled border membrane proteins chloride channel 7 (CLC-7) and the vacuolar H+-ATPase did not differ between both genotypes, but alendronate significantly enhanced the expression and PTH levels in TRPV5−/− mice. The expression of TRPV5, CLC-7, and H+-ATPase in osteoclast cultures was not affected by alendronate. The number of resorption pits was reduced in TRPV5−/− bone marrow cultures, but the response to vitamin D was similar to that in TRPV5+/+ cultures. The alendronate-induced upregulation of TRPV5 in bone together with the decreased resorptive capacity of TRPV5−/− osteoclasts in vitro suggests that TRPV5 has an important role in osteoclast function. However, our data indicate that significant bone resorption still occurs in TRPV5−/− mice, because alendronate treatment normalized bone thickness in these mice. Thus, TRPV5−/− mice are able to rescue the resulting defect in osteoclast-mediated bone resorption, possibly mediated by the long-term hypervitaminosis D or other (non)hormonal compensatory mechanisms.

J Bone Miner Res 2008;23:1815–1824. Published online on June 30, 2008; doi: 10.1359/JBMR.080613

Key words: TRPV5, osteoclast, alendronate, 1,25(OH)2D3, calcium

INTRODUCTION

Plasma Ca2+ concentration is kept within narrow limits by tight regulation of intestinal Ca2+ absorption, renal Ca2+ reabsorption, and exchange of Ca2+ from bone.1,2 The active form of vitamin D, 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3], and PTH are the main calcitropic hormones known to be involved in the maintenance of vertebrate Ca2+ homeostasis.3 The expression of TRPV5 and TRPV6 in bone was previously shown, but their physiological roles remained elusive.4,5 TRPV5 knockout (TRPV5−/−) mice displayed a profound renal Ca2+ wasting and showed a bone phenotype characterized by reduced bone thickness.5,6 Interestingly, TRPV5 ablation was recently shown to result in increased numbers and size of osteoclasts, whereas osteoclast bone resorptive capacity in tibial bone marrow cultures from TRPV5−/− mice was severely decreased.6,7 These data suggested that TRPV5 is involved in osteoclast-mediated bone resorption. However, the impaired osteoclast activity seems

The authors state that they have no conflicts of interest.

1Department of Physiology, Nijmegen Centre for Molecular Life Sciences, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands; 2Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands; 3Department of Orthopedics, Erasmus Medical Centre, Rotterdam, The Netherlands.

1815
at variance with the observed bone phenotype in TRPV5−/− mice.

TRPV5 is a highly Ca2+-selective ion channel localized at the luminal membrane of the late distal convoluted tubule (DCT) and connecting tubule (CNT) in kidney, where transcellular Ca2+ reabsorption takes place. TRPV6 is the homologous epithelial Ca2+ channel localized along the brush-border membrane of duodenum. After Ca2+ entry across the luminal membrane in kidney or intestine, Ca2+ is bound to Ca2+-binding proteins (calbindins), and this complex either diffuses or, alternatively, is translocated by vesicular transport to the basolateral membrane. Thereafter, Ca2+ is extruded to the blood compartment by the Na+/Ca2+ exchanger (NCX1) and/or the plasma membrane Ca2+-ATPase (PMCA1b).

It was recently shown that the phenotype of calbindin-D28K and calbindin-D9K knockout mice is rather mild, particularly because of compensatory upregulation of the expression of other Ca2+-transporting proteins involved in Ca2+ (re)absorption, partly induced by hormonal counter-regulation. In contrast, TRPV5−/− mice showed a clear phenotype characterized by profound renal Ca2+ wasting caused by impaired active Ca2+ reabsorption in DCT and CNT, accompanied by reduced expression of the downstream Ca2+ transporters. To further study the significance of TRPV5, we showed that, when Ca2+ entry through TRPV5 in polarized monolayers of rabbit CNT/CD is blocked with the potent inhibitor ruthenium red, this eliminated PTH-stimulated transepithelial Ca2+ transport and simultaneously decreased the expression of calbindin-D28K and the basolateral NCX1, whereas TRVP5 expression remained unaffected. Together, these data underline the importance of TRPV5 as the gatekeeper in renal active Ca2+ reabsorption and show that the Ca2+ influx through TRPV5 controls the expression of the downstream Ca2+ transport proteins. In addition, a significant hypervitaminosis D was present in TRPV5−/− mice, along with increased intestinal Ca2+ absorption. Furthermore, the hypervitaminosis D is responsible for the intestinal hyperabsorption of Ca2+ through upregulation of the intestinal Ca2+ transport proteins TRPV6 and calbindin-D9K.

Previously, we showed that, in bone, TRPV5 localizes exclusively to the ruffled border of osteoclasts. Furthermore, calbindin-D9K, calbindin-D28K, NCX1, and PMCA1b were shown to be present in these bone cells. Together with the near absence of resorption pit formation by TRPV5−/− osteoclasts, these data suggested that the transcellular Ca2+ transport machinery, and TRPV5 in particular, is essential for proper osteoclastic bone resorption.

The balance of bone formation and resorption can be clinically influenced by the administration of bisphosphonates, which are used in the treatment of malignancy-related hypercalcemia and osteolytic bone disease, primary and secondary hyperparathyroidism, Paget’s disease of bone, and osteoporosis. Because bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption, the action of these compounds in wildtype (TRPV5+/+) and TRPV5−/− mice, as well as the effects on the expression of TRPV5 and TRPV6, may add to our knowledge of the physiological role(s) of these epithelial Ca2+ channels in bone homeostasis. Furthermore, the effect of bisphosphonate treatment on renal and duodenal Ca2+ (re)absorption has not been evaluated in detail.

The aim of this study was, therefore, to determine the in vivo effect of the bisphosphonate alendronate on Ca2+ and bone homeostasis. The expression of the Ca2+ transport proteins in bone, kidney, and intestine was determined by real-time QPCR analysis and/or semiquantitative immunohistochemistry. The action of alendronate on bone morphology in TRPV5+/+ mice and, importantly, the bone phenotype in TRPV5−/− mice, was evaluated by μCT.

**MATERIALS AND METHODS**

**Alendronate treatment in TRPV5+/+ (wildtype) and TRPV5−/− mice**

TRPV5−/− mice were generated by targeted ablation of the TRPV5 gene. TRPV5+/+ mice and TRPV5−/− littermates were housed in a light- and temperature-controlled room with ad libitum access to deionized drinking water and standard pelleted chow (0.25% [wt/vol] Na; 1.1% [wt/vol] Ca). Eight-week-old TRPV5+/+ and TRPV5−/− mice were treated for 10 wk with 2 mg/kg alendronate (3-aminohydroxypropyldiene-1,1-bisphosphonate; n = 9) or vehicle (n = 9) once weekly by subcutaneous injection. At the end of the treatment period, the animals were housed in metabolic cages enabling ration feeding and collection of 24-h urine samples under mineral oil, preventing evaporation. After termination of the metabolic experiments, blood samples were taken, and the animals were anesthetized and killed by cervical dislocation. Immediately thereafter, duodenum, kidney, and femur were sampled. Kidney cortex was immediately frozen in liquid nitrogen and, in addition, renal tissue was fixated for immunohistochemistry by immersion in 1% (wt/vol) periodate-lysine-paraformaldehyde (PLP) for 2 h and 15% (wt/vol) sucrose in PBS overnight. Subsequently, kidney and duodenum samples were stored at −80°C until further processing. The animal ethics board of the Radboud University Nijmegen approved all animal studies.

**Analytical procedures**

Serum and urine Ca2+ concentrations were determined using a colorimetric assay as described previously. Na+ and Li+ concentrations were determined flame-spectrophotometrically (Eppendorf FCM 6343) and urine pH was measured using an electronic ion analyzer (Hanna Instruments, Szeged, Hungary). In addition, deoxypyridinoline (DPD) was analyzed in urine (Biomatex, San Francisco, CA, USA). Serum 1,25(OH)2D3 levels were determined with an [125I]1,25(OH)2D3 radioimmunoassay (IDS, Fountain Hills, AZ, USA) and serum PTH using an immunoradiometric assay (Immutopics, San Clemente, CA, USA).

**Real-time QPCR analysis**

Total RNA was extracted from bone, kidney, and duodenum using Trizol Total RNA Isolation Reagent (Gibco BRL, Breda, The Netherlands). Femurs, from which the
bone marrow was removed by flushing with PBS, were first homogenized using a Mikro Dismembrator S (Sartorius, Goettingen, Germany). The obtained RNA was subjected to DNase treatment and reverse transcribed. Subsequently, the cDNA was used to measure TRPV5 and TRPV6 mRNA in bone by real-time QPCR as described previously. In addition, the mRNA levels of the vacuolar H+-ATPase and the Cl– channel CLC-7, which are present in the ruffled border membrane of osteoclasts and involved in bone resorption, were determined. Furthermore, TRPV5 and calbindin-D 28K mRNA expression in kidney and TRPV6 and calbindin-D 9K mRNA levels in duodenum were determined. The mRNA expression level of the housekeeping gene hypoxanthine-guanine phosphoribosyl transferase (HPRT) was used as an endogenous control, which enabled calculation of specific mRNA expression levels as a ratio of HPRT.

Statistical analysis

Data are expressed as means ± SE. Statistical comparisons were analyzed by one-way ANOVA and Fisher’s multiple comparison; p < 0.05 was considered statistically significant. All analyses were performed using the StatView Statistical Package software (Power PC version 4.51) on an Apple iMac computer.

RESULTS

Metabolic studies in alendronate-treated TRPV5+/+ and TRPV5−/− mice

TRPV5+/+ and TRPV5−/− mice were treated for 10 wk with 2 mg/kg alendronate or vehicle by weekly subcutaneous injections. The obtained metabolic data are shown in Table 1. Genetic ablation of TRPV5 resulted in an ~10-fold increase in Ca2+ excretion compared with TRPV5+/+ mice, an enhanced urine volume, and slightly elevated serum Ca2+ levels. Alendronate treatment significantly decreased Ca2+ excretion in TRPV5−/− mice, but calciretin remained unaltered in TRPV5−/− mice. Likewise, alendronate reduced the increased diuresis in TRPV5+/− mice but not in TRPV5+/− mice. Serum Ca2+ levels, Na+ excretion, Li+ clearance, and urine pH were not affected by alendronate treatment. TRPV5−/− mice showed a significantly increased serum 1,25(OH)2D3 concentration. Alendronate treatment did not affect serum 1,25(OH)2D3 levels in TRPV5+/+ mice. TRPV5 ablation significantly increased serum 1,25(OH)2D3 levels, whereas alendronate normalized serum 1,25(OH)2D3 in these TRPV5−/− mice. Serum PTH levels were not altered in TRPV5−/− mice and alendronate-treated TRPV5−/− mice. Interestingly, alendronate markedly increased serum PTH levels in TRPV5−/− mice compared with untreated TRPV5−/− and TRPV5+/+ mice. Urine DPD levels were significantly reduced in TRPV5−/− mice compared with untreated controls.

Bone analysis

To evaluate the effect of alendronate on bone morphology in TRPV5+/+ and TRPV5−/− mice, femurs were scanned using μCT. Detailed 3D morphometric analysis showed
that trabecular thickness (Tb.Th), cortical thickness (Ct.Th), cortical volume (Ct.V.), and cortical bone volume fraction (Ct.V./Dp.V) were decreased in TRPV5−/− mice (Table 2). Treatment with alendronate increased the trabecular bone volume fraction (BV/TV), Ct.Th, and Ct.V./Dp.V in TRPV5+/+ mice, confirming the therapeutic efficacy of this bone resorption inhibitor. Interestingly, alendronate increased Tb.Th, BV/TV, Ct.Th, and Ct.V./Dp.V. in TRPV5−/− mice to levels that did not differ from untreated TRPV5+/+ mice, showing that alendronate was able to normalize the bone morphology parameters in these mice.

**mRNA expression of TRPV5 and osteoclast markers in bone and cultured osteoclasts**

Bone TRPV5 mRNA levels in femur, as determined by real-time QPCR analysis, were significantly enhanced by alendronate in TRPV5+/+ mice (Fig. 1A). In contrast, bone TRPV6 mRNA levels were unaffected by alendronate treatment (Fig. 1B). TRPV5 gene ablation did not alter the TRPV6 mRNA levels in femur. To further evaluate the effect of alendronate on osteoclasts, bone mRNA expression levels of the vacuolar H+-ATPase and the chloride channel CLC-7 were determined, which both are expressed at the ruffled border of the osteoclast and are involved in the acidification of resorption pits as part of the process of bone resorption.19,20 The vacuolar H+-ATPase (Fig. 2A) and CLC-7 mRNA expression (Fig. 2B) was not altered by TRPV5 ablation. Furthermore, alendronate treatment did not alter the expression of these osteoclast markers in TRPV5+/+ mice. In TRPV5−/− mice, however, alendronate significantly enhanced the bone vacuolar H+-ATPase and CLC-7 mRNA expression levels. To ascertain whether the above-described transcriptional regulation was the result of a direct effect of alendronate on the osteoclast, we determined the expression of these transport proteins in cultured osteoclasts treated with alendronate. In contrast to the alendronate-induced TRPV5 upregulation in bone, TRPV5 mRNA expression in cultured osteoclasts was not altered by alendronate application (Fig. 3A). Likewise, the expression of the chloride channel CLC-7 (Fig. 3B) and the vacuolar H+-ATPase (Fig. 3C) was unaltered by alendronate.

**Renal and duodenal expression of Ca2+ transporters**

Alendronate administration did not change renal TRPV5 mRNA (Fig. 4A) or protein expression (Figs. 5A and 5C) in TRPV5+/+ mice as determined by real-time QPCR and semiquantitative immunohistochemistry, respectively. TRPV5−/− mice showed significantly decreased renal calbindin-D28K mRNA (Fig. 4B) and protein expression in DCT and CNT (Figs. 5B and 5D). However, calbindin-D28K mRNA (Fig. 4B) and protein abundance (Figs. 5B and 5D) in both genotypes were not affected by alendronate. TRPV5 ablation resulted in a significantly enhanced intestinal mRNA expression of the Ca2+ transporters TRPV6 (Fig. 6A) and calbindin-D9K (Fig. 6B). In both TRPV5+/+ and TRPV5−/− mice, duodenal TRPV6 and calbindin-D9K mRNA levels were not altered by alendronate treatment.

**Murine bone marrow cultures and resorption pit assay**

When bone marrow from TRPV5+/+ and TRPV5−/− mice was cultured in the presence of FCS only, the number of resorption pits in TRPV5+/+ was lower compared with wild-type cultures (Fig. 7). The addition of 1,25(OH)2D3 to the culture medium moderately increased the number of resorption pits in both TRPV5+/+ and TRPV5−/− cultures. Further increments of the 1,25(OH)2D3 concentration ultimately reduced the number of resorption pits in cultures from both genotypes. Osteoclast numbers were increased by 1,25(OH)2D3 treatment in both TRPV5+/+ and TRPV5−/− mice (data not shown).

**DISCUSSION**

This study showed that treatment with the bone resorption inhibitor alendronate normalizes the reduced bone thickness in TRPV5−/− mice. This clearly indicated that significant bone resorption still occurs in these mice. In accor-

### Table 1. Serum and Urine Parameters During Alendronate Treatment in TRPV5+/+ and TRPV5−/− Mice

<table>
<thead>
<tr>
<th></th>
<th>TRPV5+/+ (Controls)</th>
<th>TRPV5+/+ (Alendronate)</th>
<th>TRPV5−/− (Controls)</th>
<th>TRPV5−/− (Alendronate)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Serum</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ca2+ (mM)</td>
<td>2.36 ± 0.02</td>
<td>2.39 ± 0.03*</td>
<td>2.49 ± 0.03*</td>
<td>2.54 ± 0.03*</td>
</tr>
<tr>
<td>PTH (pp/ml)</td>
<td>23 ± 8</td>
<td>14 ± 5</td>
<td>23 ± 5</td>
<td>122 ± 23†</td>
</tr>
<tr>
<td>1,25(OH)2D3 (pM)</td>
<td>395 ± 19</td>
<td>489 ± 76</td>
<td>575 ± 70*</td>
<td>364 ± 42†</td>
</tr>
<tr>
<td><strong>Urine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ca2+ excretion (μmol/24 h)</td>
<td>9.3 ± 1.3</td>
<td>7.6 ± 0.6</td>
<td>102 ± 2*</td>
<td>85 ± 3†</td>
</tr>
<tr>
<td>Na+ excretion (mmol/24 h)</td>
<td>2.2 ± 0.5</td>
<td>2.0 ± 0.3</td>
<td>6.2 ± 0.1*</td>
<td>4.6 ± 0.3†</td>
</tr>
<tr>
<td>Li+ clearance (μL/min)</td>
<td>15 ± 2</td>
<td>12 ± 1</td>
<td>17 ± 2</td>
<td>18 ± 2</td>
</tr>
<tr>
<td>pH</td>
<td>7.2 ± 0.2</td>
<td>7.3 ± 0.2</td>
<td>6.3 ± 0.3†</td>
<td>6.2 ± 0.2*</td>
</tr>
<tr>
<td>DPD (nM)</td>
<td>51 ± 12</td>
<td>29 ± 5</td>
<td>32 ± 4</td>
<td>15 ± 2†</td>
</tr>
</tbody>
</table>

† p < 0.05 vs. TRPV5+/+ controls.

* p < 0.05 vs. TRPV5−/− controls.
dance, the expression of other ruffled border transporters involved in osteoclast-mediated bone resorption (i.e., the vacuolar H^+-ATPase and ClC-7) remained unchanged in TRPV5^{−/−} mice. Interestingly, alendronate enhanced osteoclast TRPV5 expression, whereas the expression of the Ca^{2+} transporters in kidney and intestine was not affected. This indicated that alendronate specifically affects bone, without altering renal or intestinal active Ca^{2+} (re)absorption. Taken together, these data suggest that the severely impaired bone resorptive capacity that was shown in tibial bone marrow cultures from TRPV5^{−/−} mice is rescued in vivo.

Because osteoclast numbers are increased in TRPV5^{−/−} mice and these osteoclasts retain 1,25(OH)_{2}D_{3} responsiveness, the rescue mechanism might involve hyper-vitaminosis D.

Alendronate treatment during 10 wk enhanced bone thickness in TRPV5^{+/+} mice, which substantiates the therapeutic efficacy of this compound in mice. In TRPV5^{−/−} mice, alendronate normalized the significantly diminished bone thickness and volume parameters compared with TRPV5^{+/+} mice and reduced urinary excretion of the bone resorption marker DPD. Furthermore, renal Ca^{2+} excretion was diminished by alendronate in these mice, which is in line with less Ca^{2+} being released from bone because of

<table>
<thead>
<tr>
<th>TRPV5^{+/+}</th>
<th>Controls</th>
<th>Alendronate</th>
<th>TRPV5^{−/−}</th>
<th>Controls</th>
<th>Alendronate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tb.Th (µm)</td>
<td>86 ± 2</td>
<td>85 ± 2</td>
<td>79 ± 2*</td>
<td>85 ± 2</td>
<td></td>
</tr>
<tr>
<td>Tb.V. (mm³)</td>
<td>0.9 ± 0.1</td>
<td>0.9 ± 0.1</td>
<td>0.9 ± 0.1</td>
<td>1.0 ± 0.1</td>
<td></td>
</tr>
<tr>
<td>BV/TV (%)</td>
<td>22 ± 1</td>
<td>31 ± 1*</td>
<td>21 ± 2</td>
<td>28 ± 2*</td>
<td></td>
</tr>
<tr>
<td>Diaphysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ct.Th (µm)</td>
<td>281 ± 3</td>
<td>308 ± 9*</td>
<td>223 ± 5*</td>
<td>268 ± 6*</td>
<td></td>
</tr>
<tr>
<td>Ct.V (mm³)</td>
<td>4.1 ± 0.2</td>
<td>4.4 ± 0.2</td>
<td>3.4 ± 0.2*</td>
<td>4.0 ± 0.3</td>
<td></td>
</tr>
<tr>
<td>Ct.V/Dp.V (%)</td>
<td>56 ± 1</td>
<td>61 ± 1*</td>
<td>47 ± 1*</td>
<td>56 ± 1*</td>
<td></td>
</tr>
</tbody>
</table>

Bone morphometry parameters were determined by μCT. Controls, mice treated with vehicle only; alendronate, mice treated for 10 wk with alendronate (2 mg/kg weekly). In the femoral head, trabecular thickness (Tb.Th), trabecular volume (Tb.V), bone volume (BV), total bone marrow volume including trabecular (TV), and trabecular bone volume fraction (BV/TV) were determined. In the diaphysis, calculations were performed with regard to cortical thickness (Ct.Th), cortical volume (Ct.V), total diaphyseal volume (Dp.V), and cortical bone volume fraction (Ct.V/Dp.V). Data are presented as means ± SE.

* p < 0.05 vs. TRPV5^{+/+} controls.
† p < 0.05 vs. TRPV5^{−/−} controls.
inhibition of bone resorption. Previous studies showed that, in bone, TRPV5 is exclusively expressed in the osteoclast ruffled border and that osteoclasts from TRPV5^−/− mice are severely impaired in their bone resorptive capacity.\(^{(10)}\) This was exemplified by the near-absence of resorption pit formation by osteoclasts derived from bone marrow cultures of these knockout mice.\(^{(13)}\) These data suggested that TRPV5 is essential for proper osteoclastic bone resorption. The significant bone-sparing response to alendronate, however, indicated that TRPV5^−/− mice retain significant osteoclast-mediated bone resorptive capacity. This was substantiated by the unaltered expression of the vacuolar H^+-ATPase and the chloride channel CIC-7 in bones from TRPV5^−/− mice, which are expressed along with TRPV5 at the ruffled border of the osteoclast and are crucial to osteoclastic bone resorption.\(^{(19,20)}\) Moreover, mutations in these proteins have been shown to result in osteopetrosis, indicating an accelerated osteoclast differentiation pathway when present at supraphysiological levels.\(^{(28,29)}\) Indeed, TRPV5^−/− mice showed significant hypervitaminosis D, which was previously shown to counteract the renal Ca^2+ leak by inducing intestinal hyperabsorption of Ca^2+ mediated by increased duodenal expression of the homologous epithelial Ca^2+ channel TRPV6 and calbindin-D9K.\(^{(5,14)}\) In TRPV5/25–hydroxyvitamin-D_3/1α-hydroxylase double knockout mice (TRPV5^−/−/1α-OHase^−/−), in addition to TRPV5 ablation, 1,25(OH)_2D synthesis is impaired.\(^{(14)}\) The compensatory Ca^2+ hyperabsorption observed in TRPV5^−/− mice was absent in TRPV5^−/−/1α-OHase^−/− mice.\(^{(14)}\) Importantly, the latter mice showed a distinct bone phenotype including reduced bone length, along with severe hypocalcemia and hyperparathyroidism. Whereas physiological doses of 1,25(OH)_2D inhibit PTH-induced bone resorption, 1,25(OH)_2D has been suggested to stimulate bone resorption by enhancing osteoclast formation when present at supraphysiological levels.\(^{(28,29)}\) Indeed, both the number of mature osteoclasts and osteoclast precursors in bone marrow of TRPV5^−/− mice were increased, indicating an accelerated osteoclast differentiation pathway in the presence of hypervitaminosis D in these mice.\(^{(10)}\) Taken together, these data suggest that the increased 1,25(OH)_2D levels not only lead to Ca^2+ hyperabsorption but might also rescue the impaired osteoclast function, concurrently resulting in the maintenance of normocalcemia. To address this hypothesis, TRPV5^+/− and TRPV5^−/− bone

FIG. 3. mRNA expression of the epithelial Ca^2+ channel TRPV5, the vacuolar H^+-ATPase, and the Cl^− channel CIC-7 in cultured osteoclasts during treatment with alendronate. The effect of alendronate application during 24 h on mRNA expression of TRPV5 (A), H^+-ATPase (B), and CIC-7 (C) in osteoclast cultures was determined by real-time QPCR analysis, expressed as the ratio of hypoxanthine-guanine phosphoribosyl transferase (HPRT) and depicted as percentage of untreated control osteoclast cultures. Controls, osteoclasts treated with vehicle only; alendronate, mice treated for 10 wk with alendronate (2 mg/kg weekly). Data are presented as means ± SE. *p < 0.05 vs. TRPV5^+/+ controls. N = 5 osteoclast cultures per condition.

FIG. 4. mRNA expression of renal Ca^2+ transporters during treatment with alendronate in TRPV5^+/+ and TRPV5^−/− mice. The effect of alendronate treatment on renal mRNA expression of the epithelial Ca^2+ channel TRPV5 (A) and the cytosolic Ca^2+ binding protein calbindin-D_9K (CaBP_9K; B) was determined by real-time QPCR analysis, expressed as the ratio of hypoxanthine-guanine phosphoribosyl transferase (HPRT) and depicted as percentage of TRPV5^+/+ controls. Controls, mice treated with vehicle only; alendronate, mice treated for 10 wk with alendronate (2 mg/kg weekly). Data are presented as means ± SE. *p < 0.05 vs. TRPV5^+/+ controls. N = 9 animals per group.

In addition to TRPV5, TRPV6 is also expressed by osteoclasts, suggesting that TRPV6 could compensate for the absence of TRPV5 in TRPV5^−/− mice.\(^{(4,6)}\) However, the expression of TRPV6 in bone was unaltered in TRPV5^−/− mice and not affected by alendronate treatment. Importantly, TRPV5^−/− mice showed significant hypervitaminosis D, which was previously shown to counteract the renal Ca^2+ leak by inducing intestinal hyperabsorption of Ca^2+ mediated by increased duodenal expression of the homologous epithelial Ca^2+ channel TRPV6 and calbindin-D_9K.\(^{(5,14)}\) In TRPV5/25–hydroxyvitamin-D_3/1α-hydroxylase double knockout mice (TRPV5^−/−/1α-OHase^−/−), in addition to TRPV5 ablation, 1,25(OH)_2D biosynthesis is impaired.\(^{(14)}\) The compensatory Ca^2+ hyperabsorption observed in TRPV5^−/− mice was absent in TRPV5^−/−/1α-OHase^−/− mice.\(^{(14)}\) Importantly, the latter mice showed a distinct bone phenotype including reduced bone length, along with severe hypocalcemia and hyperparathyroidism. Whereas physiological doses of 1,25(OH)_2D inhibit PTH-induced bone resorption, 1,25(OH)_2D has been suggested to stimulate bone resorption by enhancing osteoclast formation when present at supraphysiological levels.\(^{(28,29)}\) Indeed, both the number of mature osteoclasts and osteoclast precursors in bone marrow of TRPV5^−/− mice were increased, indicating an accelerated osteoclast differentiation pathway in the presence of hypervitaminosis D in these mice.\(^{(10)}\) Taken together, these data suggest that the increased 1,25(OH)_2D levels not only lead to Ca^2+ hyperabsorption but might also rescue the impaired osteoclast function, concurrently resulting in the maintenance of normocalcemia.
marrow cultures were treated with different 1,25(OH)2D3 concentrations. These experiments substantiated that TRPV5−/− osteoclasts form less resorption pits, whereas their response to 1,25(OH)2D3 did not differ from TRPV5+/+ osteoclasts. The fact that TRPV5−/− osteoclasts retain the ability to enhance osteoclast numbers and resorption pit formation on stimulation by 1,25(OH)2D3 is in line with the aforementioned hypothesis. Applying increasing 1,25(OH)2D3 concentrations in 10-fold increments eventually reduced the number of resorption pits and therefore bone resorption capacity in both TRPV5+/+ and TRPV5−/− bone marrow cultures. However, 1,25(OH)2D3 levels in TRPV5−/− mice were significantly elevated but still remained within the same order of magnitude than in the wildtype animals, suggesting that this is not expected to lead to a decreased bone resorption. Thus, because osteoclasts stay responsive to 1,25(OH)2D3 and osteoclastogenesis seems to be enhanced in these mice, the hypervitaminosis D could be involved in rescuing the osteoclast phenotype in vivo.

Interestingly, TRPV5 expression in bone was increased by alendronate treatment in TRPV5+/+ mice. However, the expression of TRPV6 and the osteoclast markers CIC-7 and the vacuolar H+-ATPase was unchanged, nor was the expression of Ca2+ transporters in kidney and intestine altered. This indicated that osteoclast TRPV5 expression is specifically upregulated when bone resorption is inhibited by alendronate, substantiating that TRPV5 is important in osteoclast function. In contrast, alendronate did enhance CIC-7 and H+-ATPase expression in TRPV5−/− mice. Unlike other bisphosphonates, which affect osteoclastogenesis and induce apoptosis of mature osteoclasts, amino-bisphosphonates such as alendronate are able to prevent bone resorption without diminishing osteoclast numbers.
cessitating at least the prolonged induction of PTH secretion and the reduced release of Ca\(^{2+}\) from bone.\(^{(16,36)}\) The upregulation of these transporters likely responsible.\(^{(16,34,37)}\) This effect was hypothesized to reflect a compensatory feedback mechanism caused by the increased PTH levels, alendronate treatment was different and more exaggerated in TRPV5\(^{-/-}\) mice. Because the stimulatory effect of PTH on osteoclast acidification as well as H\(^+-\)ATPase and CLC-7 has been previously shown,\(^{(16,34,37)}\) the increased PTH levels are likely responsible.

Whereas significantly increasing PTH levels, alendronate treatment decreased the elevated serum 1,25(OH)\(_2\)D\(_3\) levels in TRPV5\(^{-/-}\) mice. Although intriguing, these hormonal changes are not readily explained. In addition, because the hypervitaminosis D maintains the compensatory Ca\(^{2+}\) hyperabsorption in TRPV5\(^{-/-}\) mice, alendronate treatment would be expected to result in downregulation of the intestinal Ca\(^{2+}\) transporters. However, the duodenal expression of these transporters remained unchanged. Tentatively, the high serum PTH or any of its downstream effects is involved in maintaining the Ca\(^{2+}\) hyperabsorption. Whereas the stimulatory effect of PTH on Ca\(^{2+}\) transporter expression and Ca\(^{2+}\) reabsorption has been shown in kidney and PTH receptors are present in intestinal cells, the stimulatory effect on intestinal Ca\(^{2+}\) absorption is debated.\(^{(42,45)}\)

These data indicate that the response to alendronate treatment is different and more exaggerated in TRPV5\(^{-/-}\) mice compared with TRPV5\(^{+/+}\) mice. It is therefore likely that alendronate-mediated inhibition of bone resorption seriously challenges the fragile Ca\(^{2+}\) balance in these mice, necessitating at least the prolonged induction of PTH secretion to ultimately maintain normocalcemia. However, the exact mechanism explaining the adapted hormone status in TRPV5\(^{-/-}\) mice remains to be elucidated and warrants further study.

Taken together, our data suggest that the impaired bone resorption by TRPV5\(^{-/-}\) osteoclasts determined in vitro is rescued to a substantial degree in TRPV5\(^{-/-}\) mice in vivo. Possibly, the hypervitaminosis D, in addition to causing Ca\(^{2+}\) hyperabsorption in intestine, is also involved in the compensatory mechanism rescuing bone resorptive capacity. The apparent interruption of this rescue mechanism by alendronate treatment, whereas increasing bone thickness, seems to critically jeopardize Ca\(^{2+}\) homeostasis, leading to several compensatory effects including increased PTH secretion. However, these data do not yet explain the bone phenotype in TRPV5\(^{-/-}\) mice.\(^{(13)}\) In the presence of an intrinsic defect of bone resorption, reduced bone formation is likely involved. Because bone formation and resorption were shown to be closely related processes, which show a considerable amount of cross-talk, an altered bone formation–resorption coupling might contribute to the reduced bone thickness.\(^{(46-49)}\) In addition, the primary renal Ca\(^{2+}\) wasting causes a negative Ca\(^{2+}\) balance, and therefore, less Ca\(^{2+}\) may be available for bone formation.\(^{(50)}\) Of note, 1,25(OH)\(_2\)D\(_3\) treatment of murine osteoblasts was previously shown to inhibit the development of a mature osteoblast phenotype and matrix mineralization.\(^{(50)}\) Further studies are needed to unravel the exact relationship between TRPV5 ablation, osteoclast and osteoblast function, serum 1,25(OH)\(_2\)D\(_3\) and PTH levels, and the reduced bone thickness in TRPV5\(^{-/-}\) mice.

ACKNOWLEDGMENTS

This work was supported by grants from the Dutch Kidney Foundation (C10.1881 and C03.6017), EURYI 2006
awarded, and the Netherlands Organization for Scientific Research (Zon-Mw 016.006.001 and 916.56.021). The authors thank the Central Animal Facility of the Radboud University Nijmegen for technical support in this study.

REFERENCES


35. Breuil V, Cosman F, Stein L, Herbert W, Nieves J, Shin V,


Address reprint requests to: René JM Bindels, PhD
286 Physiology/NCMLS
Department of Physiology
Radboud University Nijmegen Medical Centre
PO Box 9101
6500 HB Nijmegen, The Netherlands
E-mail: R.Bindels@ncmls.ru.nl

Received in original form November 20, 2007; revised form April 21, 2008; accepted June 27, 2008.